Equities research analysts expect that ImmunoGen, Inc. (NASDAQ:IMGN) will report $14.88 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for ImmunoGen’s earnings, with estimates ranging from $11.75 million to $18.00 million. ImmunoGen posted sales of $28.69 million in the same quarter last year, which would indicate a negative year over year growth rate of 48.1%. The business is scheduled to report its next earnings results on Friday, February 9th.
On average, analysts expect that ImmunoGen will report full year sales of $14.88 million for the current year, with estimates ranging from $51.50 million to $94.74 million. For the next financial year, analysts expect that the business will post sales of $84.22 million per share, with estimates ranging from $53.95 million to $137.30 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for ImmunoGen.
ImmunoGen (NASDAQ:IMGN) last issued its quarterly earnings results on Friday, February 9th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). The company had revenue of $39.40 million for the quarter, compared to analyst estimates of $39.62 million. ImmunoGen’s quarterly revenue was up 185.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.39) earnings per share.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. grew its holdings in ImmunoGen by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 331,898 shares of the biotechnology company’s stock worth $2,360,000 after acquiring an additional 1,919 shares during the period. Voya Investment Management LLC grew its holdings in ImmunoGen by 10.0% during the 2nd quarter. Voya Investment Management LLC now owns 45,066 shares of the biotechnology company’s stock worth $320,000 after acquiring an additional 4,105 shares during the period. TIAA CREF Investment Management LLC grew its holdings in ImmunoGen by 3.1% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 252,260 shares of the biotechnology company’s stock worth $1,794,000 after acquiring an additional 7,658 shares during the period. Stifel Financial Corp grew its holdings in ImmunoGen by 7.4% during the 2nd quarter. Stifel Financial Corp now owns 111,478 shares of the biotechnology company’s stock worth $791,000 after acquiring an additional 7,663 shares during the period. Finally, SG Americas Securities LLC grew its holdings in ImmunoGen by 75.7% during the 4th quarter. SG Americas Securities LLC now owns 18,416 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 7,937 shares during the period. 67.97% of the stock is owned by hedge funds and other institutional investors.
Shares of ImmunoGen (IMGN) opened at $10.54 on Tuesday. The company has a quick ratio of 2.78, a current ratio of 2.81 and a debt-to-equity ratio of -0.03. The firm has a market cap of $1,630.00, a P/E ratio of -8.12 and a beta of 2.50. ImmunoGen has a fifty-two week low of $2.31 and a fifty-two week high of $10.66.
TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/13/analysts-anticipate-immunogen-inc-imgn-will-announce-quarterly-sales-of-14-88-million.html.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.